|
MLL3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.5850999996766E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.52839999999488E-05 |
| Normal-vs-Stage2 |
6.142400E-03 |
| Normal-vs-Stage3 |
6.752800000287E-07 |
| Normal-vs-Stage4 |
2.03659999997718E-06 |
| Stage1-vs-Stage2 |
4.740200E-01 |
| Stage1-vs-Stage3 |
1.737990E-01 |
| Stage1-vs-Stage4 |
1.650800E-01 |
| Stage2-vs-Stage3 |
1.219010E-01 |
| Stage2-vs-Stage4 |
1.165770E-01 |
| Stage3-vs-Stage4 |
8.910400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.12020000006841E-07 |
| Normal-vs-AfricanAmerican |
2.139500E-02 |
| Normal-vs-Asian |
3.215500E-04 |
| Caucasian-vs-AfricanAmerican |
4.568000E-01 |
| Caucasian-vs-Asian |
7.030600E-01 |
| AfricanAmerican-vs-Asian |
6.705200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.97660000045686E-07 |
| Normal-vs-Female |
2.51009999996388E-06 |
| Male-vs-Female |
4.911800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.60130000000414E-05 |
| Normal-vs-Age(41-60Yrs) |
4.17159999999139E-06 |
| Normal-vs-Age(61-80Yrs) |
1.01279999997761E-06 |
| Normal-vs-Age(81-100Yrs) |
2.837400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.557400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.119800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.457800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.422600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.252200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.599400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.102100E-03 |
| Classical-VS-Follicular |
5.845700E-02 |
| Classical-VS-Other |
4.056200E-01 |
| Classical-VS-Normal |
8.31610000000538E-05 |
| Tall-VS-Follicular |
1.942780E-01 |
| Tall-VS-Other |
6.204800E-01 |
| Tall-VS-Normal |
2.95670000038939E-07 |
| Follicular-VS-Other |
8.674400E-01 |
| Follicular-VS-Normal |
2.0426999999934E-05 |
| Other-VS-Normal |
3.093500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.42580000001202E-06 |
| Normal-vs-N1 |
3.96019999999719E-05 |
| N0-vs-N1 |
6.941000E-01 |
|
|
